Antibody drug conjugates (ADCs)
are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Antibody drug conjugates is generally derived from the combination of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease. Antibody drug conjugates also known as anti-cancer drugs are promising and effective modalities for cancer therapies and is prepared on two major principles of antibody resistance and cell killing efficiency of highly potent active pharmaceutical ingredient (HPAPI). This report is focused on identifying market size for antibody drug conjugate globally. Increasing cancer patients and instances globally coupled with increasing R&D activities in the field of cancer treatment is one of the major drivers for the growth of the antibody drug conjugate market.
This report identifies the antibody drug conjugate market
size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to antibody drug conjugate market.
Globally North America dominated market for antibody drug conjugate in 2015 due high investment in the field for cancer treatment, better medical infrastructure and better access to the population in the region. North America was followed by Europe and Asia-Pacific as the second and third largest markets respective in 2015. Demand for antibody drug conjugate in the Asia-Pacific region is estimated to be grow fastest during the period of study and is expected to be driven by developing medical infrastructure and various initiatives by government to provide better access to the people in the region. This report on global antibody drug conjugate also covers antibody drug conjugate market size by drug phase and available drug market and also based on various geographical regions.
This report identifies all the major companies operating in the global antibody drug conjugate market. Some of the major companies’ profiles in detail are as follows:
- On the basis of phase of drug availability anti-infective drug phase this report classified as follows : Clinical and Pre-Clinical
- On the basis of availability of drugs global antibody drug conjugate market is segmented as follows: Approved Drugs (Adcetris, Kadcyla), Pipeline Drugs (T-DM1, CMC-544, CDX-011, SAR3419 and Others)
- This report on global antibody drug conjugate is also classified on the basis of infection type covering all major types of infections as follows: HIV, Hepatitis B, Hepatitis C, Urinary Tract, Respiratory Candidiasis and Other Infections
- This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for antibody drug conjugate in each of the region.
- Seattle Genetics
- Bayer HealthCare AG
- Pfizer Inc.